批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2015/09/14 |
SUPPL-11(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2015/07/29 |
SUPPL-10(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2014/12/02 |
SUPPL-9(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2012/01/06 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/05/16 |
SUPPL-6(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2003/04/21 |
SUPPL-3(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2003/04/21 |
SUPPL-2(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/01/29 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2001/02/14 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
;Orphan
|
|
|
1999/12/29 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
;Orphan
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:BEXAROTENE 剂型/给药途径:CAPSULE;ORAL 规格:75MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021055 |
001 |
NDA |
TARGRETIN |
BEXAROTENE |
CAPSULE;ORAL |
75MG |
Prescription |
Yes |
Yes |
AB |
1999/12/29
|
VALEANT LUXEMBOURG |
203174 |
001 |
ANDA |
BEXAROTENE |
BEXAROTENE |
CAPSULE;ORAL |
75MG |
Prescription |
No |
No |
AB |
2014/08/12
|
BIONPHARMA |
209861 |
001 |
ANDA |
BEXAROTENE |
BEXAROTENE |
CAPSULE;ORAL |
75MG |
Prescription |
No |
No |
AB |
2018/05/08
|
ANI PHARMS |
209886 |
001 |
ANDA |
BEXAROTENE |
BEXAROTENE |
CAPSULE;ORAL |
75MG |
Prescription |
No |
No |
AB |
2018/07/25
|
UPSHER SMITH LABS |
210105 |
001 |
ANDA |
BEXAROTENE |
BEXAROTENE |
CAPSULE;ORAL |
75MG |
Prescription |
No |
No |
AB |
2018/09/04
|
AMNEAL PHARMS NY |
203663 |
001 |
ANDA |
BEXAROTENE |
BEXAROTENE |
CAPSULE;ORAL |
75MG |
Prescription |
No |
No |
AB |
2020/06/16
|
HIKMA |
209931 |
001 |
ANDA |
BEXAROTENE |
BEXAROTENE |
CAPSULE;ORAL |
75MG |
Prescription |
No |
No |
AB |
2021/01/14
|
TEVA PHARMS USA |
208628 |
001 |
ANDA |
BEXAROTENE |
BEXAROTENE |
CAPSULE;ORAL |
75MG |
Prescription |
No |
No |
AB |
2024/09/06
|
ASCENT PHARMS INC |